title: [Prevalence of hepatitis virus infection markers in HIV-infected patients in Southern Spain].
abstract: OBJECTIVE
  To determine: (a) The prevalence of active infection by the hepatitis C virus (HCV) and hepatitis B virus (HBV) in HIV-infected patients, as well as previous exposure to hepatitis A virus (HAV), HBV and HCV. (b) The proportion of patients who have been vaccinated against HAV and/or HBV. (c) The HCV genotype distribution and the percentage of patients who have started treatment against HCV infection.
  
  
  METHODS
  All HIV-infected patients who attended the Infectious Diseases Unit of a tertiary care hospital in Southern Spain between September 2008 and February 2009 were included in a prospective cross-sectional study.
  
  
  RESULTS
  A total of 520 patients were included. Three hundred and fifty-eight (69%) patients had positive HCV antibody, while 71% of them showed detectable HCV-RNA. The HCV genotype distribution was: 153 (62%) genotype 1, 49 (20%) genotype 3, and 45 (18%) genotype 4. One hundred and thirteen (36.5%) subjects had received treatment against HCV. The prevalence of active HBV infection was 4.4%, while the exposure to HBV was 54.8%. Four hundred and thirty-seven (84%) patients had positive markers of infection of HAV. Of the patients eligible to be vaccinated, 25.6% and 22.3% patients were vaccinated against HAV and HBV, respectively.
  
  
  CONCLUSIONS
  The current prevalence of active HCV infection remains high in our area. There were no changes in the HCV genotype distribution. The number of patients with indication for HBV and HAV vaccination and receive these vaccines is low.
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España.
authors.forename: Celia
authors.initials: C
authors.lastname: Cifuentes
authors.forename: José A
authors.initials: JA
authors.lastname: Mira
authors.forename: Julio
authors.initials: J
authors.lastname: Vargas
authors.forename: Karin
authors.initials: K
authors.lastname: Neukam
authors.forename: Carmen
authors.initials: C
authors.lastname: Escassi
authors.forename: Silvia
authors.initials: S
authors.lastname: García-Rey
authors.forename: Isabel
authors.initials: I
authors.lastname: Gilabert
authors.forename: Marian
authors.initials: M
authors.lastname: González-Monclova
authors.forename: Samuel
authors.initials: S
authors.lastname: Bernal
authors.forename: Juan A
authors.initials: JA
authors.lastname: Pineda
mesh_terms: D000328:Adult; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000453:epidemiology*; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D006506:Hepatitis A / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D035922:Hepatitis A Antibodies / Q000097:blood; D006509:Hepatitis B / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D016036:Seroepidemiologic Studies; D019529:Sexuality / Q000706:statistics & numerical data; D013030:Spain / Q000453:epidemiology; D014611:Vaccination / Q000706:statistics & numerical data; D014761:Viral Hepatitis Vaccines
chemical_list: D035922:Hepatitis A Antibodies; D006510:Hepatitis B Antibodies; D018937:Hepatitis C Antibodies; D012367:RNA, Viral; D014761:Viral Hepatitis Vaccines